Fluidigm Corporation (FLDM) News
Filter FLDM News Items
FLDM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FLDM News Highlights
- For FLDM, its 30 day story count is now at 8.
- Over the past 14 days, the trend for FLDM's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- STEM, AG and BIO are the most mentioned tickers in articles about FLDM.
Latest FLDM News From Around the Web
Below are the latest news stories about Fluidigm Corp that investors may wish to consider to help them evaluate FLDM as an investment opportunity.
Fluidigm Non-GAAP EPS of -$0.01 beats by $0.17, revenue of $38.27M beats by $5.57MFluidigm press release (NASDAQ:FLDM): Q4 Non-GAAP EPS of -$0.01 beats by $0.17. Revenue of $38.27M (-14.2% Y/Y) beats by $5.57M.... |
Fluidigm Announces Fourth Quarter and Full Year 2021 Financial ResultsSOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the fourth quarter and full year ended December 31, 2021. |
Fluidigm Announces Collaboration Agreement with the Abu Dhabi Stem Cells Center to Accelerate Imaging Mass Cytometry in Development of Targeted Stem Cell TherapiesCollaboration Enables Further Expansion of Mass Cytometry in the Middle EastSOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a collaboration agreement with the Abu Dhabi Stem Cells Center (ADSCC) for development of targeted stem cell therapies and research applications utilizing two Fluidigm® mass cytometry and tissue im |
Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global InvestorsSOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy statement for a special meeting of stockholders (the “Special Meeting”) at which Fluidigm stockholders will have the opportunity to consider and vote upon various items related to the proposed and previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (“Casdi |
Worldwide Spatial OMICS Industry to 2028 - Featuring 10x Genomics, NanoString Technologies and PerkinElmer Among Others - ResearchAndMarkets.comThe "Global Spatial OMICS Market, By Sample Type, By End Use, By Technology, By Product, By Workflow, Estimation & Forecast, 2018 - 2028" report has been added to ResearchAndMarkets.com''s offering. The global spatial OMICS market held a market value of USD 230.2 million in 2020 and is estimated to reach USD 506.6 million by the year 2028. The market is anticipated to register a CAGR of 10.3% during the forecast period. Companies Mentioned 10x Genomics S2 Genomics, Inc. NanoString Technologies Seven Bridges Genomics PerkinElmer, Inc. Bio-Techne Danaher Corporation IonPath, Inc. Millennium Science Pty Ltd Akoya Biosciences, Inc. Fluidigm Corporation Diagenode Diagnostics Biognosys AG Rebus Biosystems Ultivue, Inc. BioSpyder Technologies Bruker Spatial omics combines the molecular scrutin... |
Fluidigm Corporation: Investment OpportunityNo summary available. |
Casdin Capital, Viking Global Investors Inject $250M In FluidigmFluidigm Corporation (NASDAQ: FLDM ) has approved a $250 million investment by Casdin Capital LLC and Viking Global Investors LP with zero-coupon convertible preferred shares with a conversion price of $3.40/share. The investment will significantly advance the Company''s mission through new organic and inorganic growth initiatives while optimizing its cost structure. Upon closing of Full story available on Benzinga.com |
Fluidigm announces $250M investment, rebranding to Standard BioToolsFluidigm (FLDM) announces a $250M investment by Casdin Capital and Viking Global Investors. Casdin and Viking will buy $250M of zero-coupon convertible preferred shares with… |
Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.Mission to Reinvigorate Growth through Optimization of Mass Cytometry and Microfluidics Platforms and Portfolio Expansion via Strategic Acquisitions Dr. Michael Egholm, Former CTO of Danaher Life Sciences, to Assume Role of CEO and Join Board of Directors Following Close; Alex Kim, Former President of Milliken & Company’s Healthcare Division, to Assume Role of COO Eli Casdin, CIO of Casdin Capital, and Dr. Martin Madaus, Former Chairman and CEO of Millipore and Ortho Clinical Diagnostics, to Joi |
Fluidigm Announces Preliminary Revenue Exceeding Guidance for the Fourth Quarter and Full Year 2021Fourth quarter preliminary revenue of $38.0 to $38.3 million Full year 2021 preliminary revenue of $130.3 to $130.6 million Base product and service revenue growth of approximately 13% for fourth quarter and 12% for full year as new Biomark OEM and CyTOF XT instruments contributed to revenue SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM) today announced preliminary revenue for the fourth quarter and full year ended December 31, 2021, exceeding |